Prof. Dr. med. Dr. oec. troph. Jürgen Stein

1. Caspary, W.F., Stein, J. Darmkrankheiten Springer-Verlag, Heidelberg, 1999

2. Stein, J., T. Wehrmann. Funktionsdiagnostik in der Gastroenterologie. 1. Auflage Springer-Verlag, Heidelberg, 2002

3. Stein, J., Jauch, K.W. Praxishandbuch Klinische Ernährung und Infusionstherapie. Springer-Verlag, Heidelberg, 2003

4. Caspary, W.F., Mössner, J., Stein, J. Therapie gastroenterologischer Krankheiten Springer-Verlag, Heidelberg, 2005

5. Stein, J., T. Wehrmann. Funktionsdiagnostik in der Gastroenterologie. 2. Auflage Springer-Verlag, Heidelberg, 2006

6. Caspary, W.F., Kist, M., Stein, J. Infektionskrankheiten des Gastrointestinaltraktes. Springer-Verlag, Heidelberg, 2007

7. Stein, J., Kist, M., Raithel, M.: Erkrankungen durch Nahrungs- und Genussmittel. Wissenschaftsverlag, Stuttgart , 2011

8. Stein J. Chronisch-entzündliche Darmerkrankungen – Labordiagnostik, Falk Foundation e.V. , 2011

9. Stein J. Inflammatory bowel Disease – Laboratory diagnostics, Falk Foundation e.V. , 2012

10. Stein, J. Diagnostik und Therapiekontrolle bei chronisch-entzündlichen Darmerkrankungen UNI-MED Verlag 1. Auflage; Bremen – London – Berlin, 2012

11. Stein, J., Farrag, K. Labordiagnostik in der Gastroenterologie und Hepatologie UNI-MED Verlag 1. Auflage; Bremen – London – Berlin, 2018

12. Stein, J., Farrag, K. Diagnostik und Therapiekontrolle bei chronisch-entzündlichen Darmerkrankungen UNI-MED Verlag 2. Auflage; Bremen – London – Berlin, 2019

13. Stein, J., T. Wehrmann. Labor- und Funktionsdiagnostik in der Gastroenterologie und Hepatologie. 3. Auflage, Springer-Verlag,

1. Dignass, A ., Stein, J. Chronisch-entzündliche Darmerkrankungen. Gastroenterologie update 2000: Extraintestinale Manifestationen. Springer-Verlag, Heidelberg, 2000.

2. Morgan, D.M.L., Milovic, V. Stein, J. : Biologically active amines in food. (Vol. V) COST 917 – European Commission 2001.

3. Stein, J. , Dignass, A ., Chronisch-entzündliche Darmerkrankungen. Gastroenterologie update 2001: Infektionskrankheiten. Springer-Verlag, Heidelberg, 2001.

4. Dignass, A ., Stein, J., Chronisch-entzündliche Darmerkrankungen. Gastroenterologie update 2002: Neue therapeutische Strategien. Springer-Verlag, Heidelberg , 2002

Stein, J., Stoll, R.: Epitheliale Transportfunktionen im Magen-Darm-Trakt. Z. Gastroenterol ., 1994 (Suppl. 4)

Stein, J., Schulzke, J.D.: Epitheliale Transportfunktionen im Magen-Darm-Trakt Z. Gastroenterol ., 1996 (Suppl. 3)

Stein, J., Schulzke, J.D.: Epitheliale Transportfunktionen im Magen-Darm-Trakt Z. Gastroenterol ., 1998 (Suppl. 1)

Stein, J., Schulzke, J.D.: Epitheliale Transportfunktionen im Magen-Darm-Trakt Z. Gastroenterol ., 2011 (Suppl. 1)

Stein, J., Dignass, A: Probiotika. Pharm Unserer Zeit ., 2012 Stein, J., Farrag, K: Chronisch entzündliche Darmerkrankungen. Pharmakon

Stein J. Ernährung bei CED – 20 Fragen, 20 Antworten (Falk)

Stein J. Ernährung bei Morbus Crohn (Abbott)

Stein J. Eisen bei chronischen Magen-Darmerkrankungen (Vifor) Stein J. Ernährungsmedizinische Aspekte bei Chronisch-entzündlichen Darmerkrankungen ( MSD ) 2013

Farrag K, Wächtershäuser A., Ulrich, S. Stein, J. Frankfurter Schulungsprogramm Zöliakie 2019 (6. Überarbeitete Auflage)

1. Stein J , Farrag K, Blumenstein I. Neue CED-Therapien – was kommt nach den Biologika? Pharmakon 2021;9:30-38.

2. Stein J , Ehehalt R. Gewürze und Verdauung. Pharmakon 2021;9:30-38.

3. Farrag K, Stein J . Phytotherapeutika in der CED-Therapie. Pharmakon 2021;9:67 – 76.

4. Aksan A, Farrag K, Blumenstein I, et al. Chronic intestinal failure and short bowel syndrome in Crohn’s disease. World J Gastroenterol 2021;27:30-48.

5. Aksan A, Farrag K, Blumenstein I, et al. Chronic intestinal failure and short bowel syndrome in Crohn’s disease. World J Gastroenterol 2021;27:in press.

6. Aksan A, Farrag K, Aksan S, et al. Flipside of the Coin: Iron Deficiency and Colorectal Cancer. Front Immunol 2021;12:635899.

7. Kucharzik T, Dignass AU, Atreya R, et al. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-e326.

8. Kucharzik T, Dignass AU, Atreya R, et al. Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Z Gastroenterol 2020;58:672-692.

9. Farrag K, Stein J. Eisenmangelanämie. Gastro-News 2020; 07 36-47.

10. Kucharzik T, Dignass AU, Atreya R, et al. [August 2019 – AWMF-Registriernummer: 021-009]. Z Gastroenterol 2019;57:1321-1405.

11. Farrag K, Shastri YM, Beilenhoff U, et al. Percutaneous endoscopic gastrostomy (PEG): a practical approach for long term management. BMJ 2019;364:k5311.

12. Farrag K, Raithel M, Stein J. Nahrungsmittelallergien – Welche Tests sollte der Gastroenterologe durchführen. Verdauungskrankheiten 2019;37:101-108.

13. Farrag K, Lipp HP, Stein J. Neue Optionen der oralen Eisensubstitution. AMT 2019;37:105- 112.

14. Authors, Collaborators. Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). Z Gastroenterol 2019;57:162-241.

15. Aksan A, Farrag K, Stein J. An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2019;13:95-97.

16. Stein J, Schulzke JD, Schuppan D. [Drug therapy in coeliac disease – “from bench to bedside”]. Z Gastroenterol 2018;56:151-164.

17. Hollenbach M, Prettin C, Gundling F, et al. Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC Gastroenterol 2018;18:118.

18. Farrag K, Stein J. Eisenmangel – Bedeutung für die Gastroenterologie. Kompendium Gastroenterologie 2018;14:73-81.

19. Farrag K, Stein J. Diagnosis and Management of Celiac Disease. Pharmakon 2018;6:109-117.

20. Dignass A, Farrag K, Stein J. Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. Int J Chronic Dis 2018;2018:9394060.

21. Stein J, Aksan A, Farrag K, et al. Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother 2017;18:1721-1737.

22. Martin J, Radeke HH, Dignass A, et al. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2017;11:19-32.

23. Büning C, Stein J. Eisen(III)-Maltol: Ein neu zugelassenes dreiwertiges Eisenpräpart zur oralen Behandlung der Eisenmangelanämie bei erwachsenen Patienten mit CED. Drug Report 2017;9:1-12.

24. Worm N, Stein J, Ströhle A. Nichtalkoholische Fettleberekrankung. Ernährung und Medizin 2016;31:67 – 72

25. Worm N, Stein J, Strohle A. Nonalcoholic Fatty Liver Disease. Diabetes Stoffwechsel Und Herz 2016;25:85-94.

26. Stein J, Connor S, Virgin G, et al. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol 2016;22:7908-25.

27. Schulte-Bockolt A, Soergel KH, Stein J. Internal medicine in the United States and Germany: mutual influences from 1870 to today. Wien Med Wochenschr 2016;166:479-486.

28. van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version). Rev Gastroenterol Mex 2015;80:74-106.

29. Ströhle A, Stein J. Nichtalkoholische Fettleberekrankung. MMP 2015;38:166–178.

30. Stein J, Dignass AU. Laboratory Diagnostics in IBD – What the Gastroenterologist Should Know. Eur Gastroenterol J 2015:31-47.

31. Stein J, Dignass AU. Anaemia in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2015;13:308-18.

32. Renner F, Rogler G, Stein J. Stellenwert des Calprotectin-Tests in der diagnostischen Abklärung gastrointestinaler Erkrankungen für die tägliche Praxis. UpDate 2015;4:1-11.

33. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9:211-22.

34. Stein J, Stier C, Raab H, et al. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014;40:582-609.

35. Stein J, Schuppan D. Coeliac Disease – New pathophysiological Findings and their implications for Therapy. Viszeralmedizin 2014;30:156-165.

36. Stein J, Schulzke JD. The small intestine as digestive, absorptive, endocrine and immunological organ. Verdauungskrankheiten 2014;32:4-16.

37. Stein J, Arlt A. Anämien – Modul 3: Megaloblastäre Anämien. eCur Innere Med 2014:1-25.

38. Stein J, Arlt A. Anämien – Modul 2: Eisenmangelanämien. eCur Innere Med 2014:1-25.

39. S. Chiappetta S, s: S, J. S. Emerging options for the treatment of ulcerative colitis. Drugs of the Future 2014.

40. Rohrig G, Steinmetz T, Stein J, et al. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies]. MMW Fortschr Med 2014;156 Suppl 2:48-53.

41. Preiss JC, Bokemeyer B, Buhr HJ, et al. [Updated German clinical practice guideline on “Diagnosis and treatment of Crohn’s disease” 2014]. Z Gastroenterol 2014;52:1431-84.

42. Blumenstein I, Shastri YM, Stein J. Gastroenteric tube feeding: Techniques, problems and solutions. World J Gastroenterol 2014;20:8505-8524.

43. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7:1-33.

44. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease – a practical approach. Ann Gastroenterol 2013;26:104-113.

45. Stein J, Arlt A. Anämien – Modul 1: Praxisorientierte Klassifikation und Differenzialdiagnostik. eCur Innere Med 2013:1-22

46. Roehrig G, Stein J, Steinmetz T, et al. Studies on the Efficacy and tolerability of Intravenous High-Dose iron therapy in geriatric Patients with Iron deficiency anemia. Internist 2013;54:124-125.

47. Geisel T, Bach M, Schulze B, et al. Diagnosis and Treatment of Iron deficiency anemia in geriatric Patients. Results of a retrospective single-center Study. Internist 2013;54:126-126.

48. Stein J, Dignass A. Pravention und Therapie von entzundlichen Magen-/Darm-Erkrankungen. Pharm Unserer Zeit 2012;41:123-133.

49. Stein J, Dignass A. Wie sicher sind Probiotika? Pharm Unserer Zeit 2012;41:146-148.

50. Stein J, Dignass A. Probiotika. Prävention und Therapie von entzündlichen Magen- und Darmerkrankungen. PharmUnserer Zeit 2012;41:15-25.

51. Stein J. Diagnosis work-up of iron deficiency anemia in patients with inflammatory bowel disease. Clin Labaratory intern (CLi) 2012:26-28.

52. Dignass A, Hartmann F, Schulze H, et al. Trichuris suis ova bei chronisch-entzundlichen Darmerkrankungen. Pharm Unserer Zeit 2012;41:154-157.

53. Wiesenthal M, Diehl D, Loitsch S, et al. Impaired iron absorption in inflammatory bowel disease. Z Gastroenterol 2011;49:S5-S6.

54. Stein J, Winckler K, Teuber G. Komplikationen und metabolische Störungen nach bariatrischen Operationen aus gastroenterologischer Sicht. Der Gastroenterologe 2011;6:33- 39.

55. Stein J, Hartmann F, Dignass A. Management of iron deficient anemia in IBD with special emphasis on intravenous iron. Pract Gastroenterol 2011:17-30

56. Stein J. The Utility of Faecal Calprotectin in the Diagnosis and Therapy of IBD. Clin Lab Int 2011:20-21.

57. Kaminski BM, Steinhilber D, Stein JM, et al. Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol 2011;13:137-46.

58. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7:599-610.

59. Stein JM, Hartmann F, Cordes HJ, et al. [Pathophysiological-based diagnosis and therapy of iron-deficient anaemia in inflammatory bowel disease]. Z Gastroenterol 2009;47:228-36.

60. Stein J, Boehles HJ, Blumenstein I, et al. Amino acids – Guidelines on Parenteral Nutrition, Chapter 4. Ger Med Sci 2009;7:Doc24.

61. Dignass AU, Hartmann F, Sturm A, et al. Management of inflammatory bowel diseases during pregnancy. Dig Dis 2009;27:341-6.

62. Wachtershauser A, Stein JM. [Nutritional factors and nutritional therapy for irritable bowel syndrome–what is worthwhile?]. Z Gastroenterol 2008;46:279-91.

63. Stein J, Loitsch S, Shastri Y. Non-invasive detection of colorectal cancer – do we still need the guaiac-based fecal occult blood test? J Lab Med 2008;32:158-167.

64. Loitsch SM, Shastri Y, Stein J. Stool test for colorectal cancer screening–it’s time to move! Clin Lab 2008;54:473-84.

65. Wachtershauser A, Stein J. [The use of fish oil in lipid metabolism disorders]. Pharmazie in unserer Zeit 2007;36:126-32.

66. Wachtershauser A, Stein J. [Lipid and lipoprotein metabolism]. Pharm Unserer Zeit 2007;36:98-107.

67. Stein JM, Schneider AR. [Bacterial overgrowth syndrome]. Z Gastroenterol 2007;45:620-8.

68. Stein J, Rosch W. [H2 blockers and antacids in gastrointestinal diseases]. Pharm Unserer Zeit 2007;36:38-43.

69. Stein J, Kist M. Diarrhea – clinical presentation and diagnostic strategies. Verdauungskrankheiten 2007;25:192-213.

70. Stein J. Stressulkusprophylaxe. Intensiv- und Notfallmed 2007:57-61.

71. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-53.

72. Caspary WF, Stein J. Functional tests to detect small bowel diseases. Verdauungskrankheiten 2007;25:17-33.

73. Caspary WF, Stein J. Funktionstests bei Verdacht auf Dünndarmkrankheiten. Verdauungskrankheiten 2007;25:17-33.

74. Wachtershauser A, Stein J. [Interdisciplinary obesity treatment]. Pharmazie Unserer Zeit 2006;35:506-10.

75. Stein J. [Clinical features and diagnosis of celiac disease]. Internist (Berl) 2006;47:929-7; quiz 938.

76. Schroder O, Gerhard R, Stein J. [Antibiotic-associated diarrhea]. Z Gastroenterol 2006;44:193- 204.

77. Ulrich S, Wolter F, Stein JM. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol Nutr Food Res 2005;49:452-61.

78. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-9.

79. Bozkurt S, Stein J, Teuber G. [Hepatic hydrothorax]. Z Gastroenterol 2005;43:1319-28.

80. Wolter F, Ulrich S, Stein J. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in colorectal cancer: key role of polyamines? J Nutr 2004;134:3219-22.

81. Wachtershauser A, Stein J. Dietary recommendations in disorders of the lipid metabolism, Part 2: Nutrition therapy. Ernahrungs-Umschau 2004;51:144-+.

82. Schroder O, Hoepffner N, Stein J. Enteral nutrition by endoscopic means; I. Techniques, indications, types of enteral feed. Z Gastroenterol 2004;42:1385-92.

83. Schneider AR, Caspary WF, Stein J. [(13)C-breath tests for the assessment of liver function]. Z Gastroenterol 2004;42:269-75.

84. Hoepffner N, Schroder O, Stein J. Enteral Nutrition by Endoscopic Means; II. Complications and Management. Z Gastroenterol 2004;42:1393-8.

85. Stein J, Braden B. Funktionsdiagnostik bei Erkrankungen des exokrinen Pankreas. Akt Ern Med 2003;28:79-86.

86. Stein J. Autoaggressionskrankheiten. Wenn der Körper sich selbst zerstört. Colitis ulcerosa und Morbus Crohn. DAZ 2003;143:60-63.

87. Stein J. Nutrition. Z Gastroenterol 2003;41:62-68.

88. Stange EF, Schreiber S, Folsch UR, et al. Diagnostics and treatment of Crohn’s disease – Results of an evidence-based consensus conference of the German Society for Digestive and Metabolic Diseases. Z Gastroenterol 2003;41:19-20.

89. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003;98:530-7.

90. Schirrmacher S, Blumenstein I, Stein J. [Pathogenesis and treatment of pruritus in patients with cholestasis]. Z Gastroenterol 2003;41:259-62.

91. Gaschott T, Stein J. Short-chain fatty acids and colon cancer cells: the vitamin D receptor– butyrate connection. Recent Results Cancer Res 2003;164:247-57.

92. Bott C, Lembcke B, Stein J. [Colorectal cancer and folate]. Z Gastroenterol 2003;41:263-70.

93. Wolter F, Stein J. Biological activities of resveratrol and its analogs. Drugs of the Future 2002;27:949-959.

94. Wachtershauser A, Bargon JG, Stein J. Diets for patients with cystic fibrosis. Ernahrungs- Umschau 2002;49:380-+.

95. Stein J, Höpffner N. Nutrition enterale par voie endoscopique. Indications et limites. Acta Endoscopica 2002;32:719- 737.

96. Schröder O, Stein J. Erbrechen in der Schwangerschaft. MMW Fortschr Med 2002;50:32-34.

97. Schroder O, Stein J. [Vomiting in pregnancy. When is it more than only a bothersome nuisance?]. MMW Fortschr Med 2002;144:32-4.

98. Milovic V, Faust D, Caspary WF, et al. Chemoprevention in colorectal cancer. Arch Gastroenterohepatol 2001;20:24-26.

99. Breitkreutz R, Faust D, Brandstätter M, et al. Ernährungsmedizin im Internet. Akt Ernähr Med 2001;26:271-278.

100. Wolter F, Caspary WF, Stein J. Nahrungsmittelunverträglichkeiten. . Internis Prax 2000;41:271-280.

101. Wachtershauser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr 2000;39:164-71.

102. Stein J, Bolder U. Intestinal functions in the critically ill patients. Chirurgische Gastroenterologie 2000;16:13-22.

103. Schröder O, Sohn CR, Stein J. Gastrointestinale und hepatobiliäre Komplikationen in der Schwangerschaft. Geburtsh Frauenheil 2000;60:333-344.​

104. Weinand I, Stein J. [Cholysarkosin in treatment of bile acid deficiency syndrome]. Z Gastroenterol 1999;37:675-7.

105. Wachtershauser A, Stein J. [Nonsteroidal anti-rheumatic drugs and colon carcinoma: COX versus PPAR]. Z Gastroenterol 1999;37:257-61.

106. Stein J. Chemically defined structured lipids: current status and future directions in gastrointestinal diseases. Int J Colorectal Dis 1999;14:79-85.

107. Schroeder O, Stein J. Antibiotic-associated diarrhea and pseudomembraneous enterocolitis. Verdauungskrankheiten 1999;17:265-274.

108. Schroder O, Stein J. Methotrexate in the therapy of gastrointestinal diseases. Zeitschrift Fur Gastroenterologie 1999;37:623-637.

109. Milovic V, Stein J, Caspary W. Intestinal malabsorption: Pathophysiology, clinical signs and symptoms, diagnosis and treatment (second part). . Arch. Gastroenterohepatol 1999;18.

110. Milovic V, Stein J, Caspary W. Intestinal malabsorption: Pathophysiology, clinical signs and symptoms, diagnosis and treatment (first part). . Arch. Gastroenterohepatol 1999;18:65 – 74.

111. Jordan A, Caspary WF, Stein J. [Tube feeding in malnutrition]. Zeitschrift fur Gerontologie und Geriatrie 1999;32 Suppl 1:I69-74.

112. Caspary WF, Stein J. Diseases of the small intestine. Eur J Gastroenterol Hepatol 1999;11:21- 5.

113. Milovic V, Stein J. Conditionally immortalised intestinal epithelial cells: a new model for studying intestinal epithelial cell turnover. . Z Gastroenterol 1998;36 73-76.

114. Gerhard R, Ries J, Kottra G, et al. Kaliumkanäle, Aktinfilamente in der Regulation intestinaler Schlussleisten. . Z Gastroenterol 1998;36 54-57.

115. Feldhaar H, Stein J. [Stress proteins and molecular chaperones–protectors of intestinal epithelial damage?]. Z Gastroenterol 1998;36:193-5.

116. Weinand I, Jordan A, Caspary WF, et al. Dietary factors in the pathogenesis of inflammatory bowel disease. Zeitschrift Fur Gastroenterologie 1997;35:637-649.

117. Stein J, Spirchez Z, Lembcke B, et al. Untersuchungen zur Bedeutung der Elastase- Bestimmung als einen neuen nicht-invasiven Test der exokrinen Pankreasinsuffizienz. Z Gastroenterol 1997:122-129.

118. Stein J, Kottra G. Intestinal tight junctions .1. Structure and molecular regulation mechanisms. Zeitschrift Fur Gastroenterologie 1997;35:205-220.

119. Stein J, Caspary W. Fecal tests in the diagnosis of exocrine pancreatic insufficiency. . Clin Lab 1997;43:361-368.

120. Stein J, Caspary W. Enterales Eiweißverlustsyndrom. Diagnostik und Therapie. . Akt Ernähr Med 1997;22:1-10.

121. Schröder O, Stein J. Klinische Manifestation von Störungen im Haushalt kurzkettiger Fettsäuren. . Akt Ernähr Med 1997;22:86-96.

122. Jordan A, Stein J. Pathophysiology of tumor cachexia. Ernahrungs-Umschau 1997;44:250-&.

123. Jordan A, Stein J. Nutrition of tumor patients: New dietetic strategies. Ernahrungs-Umschau 1997;44:289-&.

124. Jordan A, Stein J. Complications of enteral nutrition in tumor patients. Ernahrungs-Umschau 1997;44:327-&.

125. Stein J, Schoonbroodt D, Jung M, et al. [Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function]. Gastroenterol Clin Biol 1996;20:424-9.

126. Stein J. Where to place human elastase-1 in the diagnosis of pancreatic insufficiency. Z Gastroenterol 1996;34 1-7.

127. Stein J. Near-infrared reflectance analysis. A new investigative tool in diagnosis of malabsorption syndromes. Z Gastroenterol 1996;34:8-13.

128. Lembcke B, Braden B, Stein J, et al. Pancreatic function tests: Indirect tests, fecal fat analysis, secretin-pancreozymin-test. Verdauungskrankheiten 1995;13:248-255.

129. Lembcke B, Braden B, Stein J. Diagnosing Steatorrhea. Z Gastroenterol 1994;32:256-261.​

130. Gebhardt B, Ries J, Caspary W, et al. Sauerstoffradikale, NO und posthypo-xämische Permeabilität. Zellschädigung oder Regulation ? Z Gastroenterol 1994;32:S47-53.

131. Stein J, Daniel H. [Physiology of digestion]. Krankenpfl J 1986;24:10-4.

1. Farrg K, Stein J. Nahrungsmittelallergie. In: S. Jonas FL, ed. Viszeralmedizin: Springer-Verlag, Berlin, Heidelberg, New York 2021:276-286.

2. Stein J, Schröder O. Prüfung der Leberdurchblutung und des Porto-systemischen Shuntvolumens. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2020:225-232.

3. Stein J, Mavrommataki I. Prüfung der Aktivität von Fibrinogenese und Fibrose. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2020:197-208.

4. Stein J, Farrag K, Schröder O. Prüfung der biliären Sekretionsleistung – Ikterus und Cholestase. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2020:187 – 196.

5. Stein J, Farrag K. Prüfung der hepatozellulären Integrität. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2020:181 – 186.

6. Stein J, Braden B. Prüfung der Syntheseleitung und metabolischen Kapazität. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2020:200-224.

7. Farrag K, Ulrich-Rückert S, Stein J. Gastrointestinale Erkrankungen. In: Wirth A, Hauner H, eds. Adipositas 5. ed. Berlin, Heidelberg Springer-Verlag 2020:224-230.

8. Farrag K, Stein J. Medical Therapy of GERD. In: Horgan S, Fuchs KH, eds. Management of Gastroesophageal Reflux Disease. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2020:39-46.

9. Farrag K, Stein J. Medical treatment. In: Santiago Horgan K-HF, ed. Management of Gastroesophageal Reflux Disease: Surgical and Therapeutic Innovations. Berrlin, New York: Springer, 2020.

10. Farrag K, Stein J. Nahrungsmittelallergie. In: Viszeralmedizin In: F. v. Weizäcker SJ, ed. Viszeralmedizin. 2nd ed. Berlin, Heidelberg, New York Springer-Verlag, 2020:276-286.

11. Farrag K, Stein J. Resorptionstests. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2020:113 – 152.

12. Farrag K, Stein J. Kurzdarmsyndrom – Darmversagen. In: Hofmann JC, Klump B, Kroesen A, Siegmund B, eds. Chronisch-entzündliche Darmerkrankungen. 3. ed. Berlin, Heidelberg, New York: Springer, 2020:485-513.

13. Farrag K, Stein J. Strukturelle Grundlagen der Leberfunktion. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2020:175-180.

14. Farrag K, Braden B, Stein J. Art und Durchführung von Pankreasfunktionsprüfungen. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 3. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2020:153-174.

15. Aksan A, Farrag K, Shastri Y, et al. Percutaneous Endoscopic Gastrostomy (PEG). Encyclopedia of Gastroenterology. 2nd ed. New York: Elsevier B.V, 2020:208-216.

16. Farrag K, Stein J. Nicht-Zöliake-Nicht-Weizenallergie-Weizensensitivität. In: Riemann J, Fischbach W, Galle P, Mösser J, eds. Referenz Gastroenterologie. Stuttgart: Georg Thieme Verlag, 2019:369-372.

17. Farrag K, Stein J. Zöliakie. In: Riemann J, Fischbach W, Galle P, Mösser J, eds. Referenz Gastroenterologie. Stuttgart: Georg Thieme Verlag, 2019:361-368.

18. Farrag K, Dignass AU, Stein J. Labordiagnostik. In: Stein J, Farrag K, eds. Diagnostik und Therapiesteuerung bei chronisch-entzündlichen Darmerkrankungen 2. ed. Bremen: Uni-med Verlag, 2019:12-63.

19. Stein J, Kist M, Lembcke B. Diarrhö – Leitsymptome und diagnostisches Vorgehen. In: Stein J, Farrag K, eds. Labordiagnostik in der Gastroenterologie und Hepatologie. Volume 1. Bremen- London-Boston: UNI-MED Verlag AG, 2018:98-139.

20. Stein J, Farrag K, Ulrich-Rückert S. Ernährungstherapie bei Morbus Crohn und Colitis ulcerosa. In: Kucharzik T, Rijcken E, Bettenworth D, Senninger H, eds. Therapie chronisch entzündlicher Darmerkrankungen. Berlin/Boston: Walter de Gruyter, 2018:493-512.

21. Stein J, Farrag K. Anämie. In: Stein J, Farrag K, eds. Labordiagnostik in der Gastroenterologie und Hepatologie. Volume 1. Bremen-London-Boston: UNI-MED Verlag AG, 2018:85-97.

22. Sarazin C, Stein J. Erhöhte Leberwerte – Leberversagen. In: Stein J, Farrag K, eds. Labordiagnostik in der Gastroenterologie und Hepatologie. Volume 1. Bremen-London- Boston: UNI-MED Verlag AG, 2018:40-84.

23. Farrag K, Stein J. Nicht-Zöliakie-Nicht-Weizenallergie-Weizensensitivität. In: Riemann J, Fischbach W, Galle P, Mösser J, eds. Referenz Gastroenterologie. Stuttgart: Georg Thieme Verlag, 2018.

24. Farrag K, Stein J. Tumormarker. In: Stein J, Farrag K, eds. Labordignostik in der Gastroenterologie und Hepatologie. Bremen: UNI-MED, 2018:140-155.

25. Stein J. Labordiagnostik. In: Stange ED, ed. Entzündliche Darmerkrankungen. Stuttgart: Schattauer, 2016:54-71.

26. Stein J. Kurzdarmsyndrom – Chronisches Darmversagen. In: E.D. S, ed. Entzündliche Darmerkrankungen. Stuttgart: Schattauer, 2016:361-386.

27. Stein J. Nahrungsmittelallergie. In: J.F. Erkenbrecht SJ, ed. Viszeralmedizin: Springer-Verlag, Berlin, Heidelberg, New York 2015:276-286.

28. M. Kist AA, I. B. Autenrieth, Chr. von Eichel-Streiber, J. Frick, A. Fruth, E. O. Glocker, G. Gorkiewicz, A. von Graevenitz, M. Hornef, H. Karch, E. Kniehl, G. Mauff, A. Mellmann, L. von Müller, T. Pietzcker, R. Reissbrodt, , H. Rüssmann ES, J. Stein, N. Wüppenhorst. Gastrointestinale Infektionen – Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. In: Mauch HP, Andreas / Herrmann, Mathias / Kniehl, Eberhard, ed. MIQ 09. 2th ed: Urban & Fischer in Elsevier 2014:1-100.

29. Stein J, Dignass AU. Labordiagnostik. In: Stein J, ed. Diagnostik und Therapiesteuerung bei chronisch-entzündlichen Darmerkrankungen 1. ed. Bremen: Uni-med Verlag, 2012:12-48.

30. Stein J, Caspary WF. Resorptionstests. In: Siewert JR, Harder F, M. R, eds. Praxis der Visceralchirurgie 4. Auflage ed. Berlin, Heidelberg, New York Springer-Verlag, 2012.

31. Schröder O, Stein J. IBD and Anemia – Clinical aspects. In: Gasche C, ed. Anemia in inflammatory Bowel Diseases. 2nd ed. Bremen: UNI-MED, 2012:17-23.

32. Wolter F, Stein J. Erkrankungen durch Mykotoxine. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:430-438.

33. Wächtershäuser A, Ulrich S, Stein J. Kohlenhydrat-Intoleranzen. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel. 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:37-64.

34. Ulrich S, Wolter F, Stein J. Intoxikationen durch Pilze. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:164 – 182

35. Ulrich S, Stein J. Zöliakie. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:19-36.

36. Ulrich S, Scheppach W, Stein J. Tumorfördende Wirkungen verschiedener Nahrungsmittel. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed: Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 2011:439-459.

37. Stein J, Brodt HR, Kist M. Listeriose. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, , 2011:281 – 288.

38. Stein J. Gesundheitsschädliche Wirkungen durch Verunreinigungen und Rückstände: Arzneimittel. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:236 – 240.

39. Stein J. Erkrankungen durch Bakterientoxine. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:254 – 261.

40. Stein J. Gesundheitsschädliche Stoffe in (natürlichen) Genussmitteln. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: .) Wissenschaftliche Verlagsgesellschaft mbH, 2011:82 – 134.

41. Schulze B, Brackmann J, Bach M, ., et al. Durch Viren verursachte Erkrankungen. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:388 – 407.

42. Kist M, Stein J. Enteritis durch Pleisiomonas shigelloides. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Verlagsgesellschaft mbH, 2011:325 – 333.

43. Kist M, Stein J. Escherichia-coli-Infektionen. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:312 – 318.

44. Kist M, Stein J. Shigellen-Enteritis. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:308 – 312.

45. Gaschott T, Stein J. Veränderungen von Arzneimittelwirkungen durch Nahrungs- und Genussmittel. In: Stein J, Raithel M, Kist M, eds. Erkrankungen durch Nahrungs- und Genussmittel 1. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2011:460- 472.

46. Milovic V, Stein J. Gastrointestinal Disease and Dosage Form Performance. In: Dressman JB, Reppas C, eds. Oral Drug Absorption: Prediction and Assessment, 2nd Edition. Volume 193, 2010:127-137.

47. Behnken I, Stein J. Grundlagen. In: Weiner RA, ed. Adipositaschirurgie 1. Auflage ed: Urban&Fischer, 2010:2 – 19.

48. Stein J, Hartmann F. Kurzdarmsyndrom. In: Hofmann JC, ed. Chronisch-entzündliche Darmerkrankungen. Stuttgart: Thieme, 2009:100-119.

49. Schneider AR, Stein J. Ulkus und Ulkuskomplikationen. In: Riemann J, Fischbach W, Galle P, Mössner J, eds. Klinische Gastroenterologie Volume 1. Stuttgart: Georg Thieme Verlag, 2008:525-557.

50. Blumenstein I, Stein J. Parenterale und enterale Ernährung. In: Riemann J, Fischbach W, Galle P, Mössner J, eds. Klinische Gastroenterologie Volume 1. Stutgart: Georg Thieme Verlag 2008:967-1014.

51. Stein J. Krankheiten des Dünndarmes. In: Gerok W, Huber C, Meinertz T, Zeidler H, eds. Die Innere Medizin 11. Auflage ed. Stuttgart, New York: Schattauer Verlag, 2007:529-558.

52. Stein J, Wächtershäuser A. Enterales Eiweißverlustsyndrom. In: Schauder P, Ollenschläger G, eds. Ernährungsmedizin München, Jena: Urban&Fischer, 2006:1036-1037.

53. Stein J, Wächtershäuser A. Ernährung bei bakterieller Fehlbesiedlung. In: Schauder P, Ollenschläger G, eds. Ernährungsmedizin. München, Jena: Urban&Fischer, 2006:1033-1035.

54. Stein J, Schröder O. Antibiotikaassoziierte Diarrhö und pseudomembranöse Kolitis. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:265-276.

55. Stein J, Schröder O. Resorptionstests. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:125- 180.

56. Stein J, Schröder O. Prüfung der biliären Sekretionsleistung. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2006:239-252.

57. Stein J, Schröder O. Prüfung der Leberdurchblutung und des Porto-systemischen Shuntvolumens. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:275-284.

58. Stein J, Lembcke B. Milchzuckerunverträglichkeit. In: Schauder P, Ollenschläger G, eds. Ernährungsmedizin München, Jena: Urban&Fischer, 2006:809-812.

59. Stein J, Kist M. Shigellenenteritis. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:245- 248.

60. Stein J, Kist M. Helicobacter heilmannii (früher: Gastrospirrilium hominis) und andere Helicobacter spezies. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:185- 170.

61. Stein J, Jordan A. Divertikulose. In: Schauder P, Ollenschläger G, eds. Ernährungsmedizin Urban&Fischer: München, Jena, 2006:1038-1040.

62. Stein J, Brodt HR. Plesiomonasshigelloides. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:253-254

63. Stein J, Brodt HR. Arcobacter. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York Springer-Verlag, 2006:249-250.

64. Stein J, Brodt HR. Listeriosis monocytogenes. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes !: ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:241-244.

65. Stein J, Brodt HR. Yersiniose. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:218-224.

66. Stein J, Braden B. Prüfung der Syntheseleitung und metabolischen Kapazität. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:257-274.

67. Stein J, Braden B. Art und Durchführung von Pankreasfunktionsprüfungen. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:181-212.

68. Stein J, Bott C. Chronisch-entzündliche Darmerkrankungen. In: Schauder P, Ollenschläger G, eds. Ernährungsmedizin München, Jena: Urban&Fischer, 2006:1023 – 1032.

69. Stein J. Prüfung der Aktivität von Fibrinogenese und Fibrose. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2006:253-256.

70. Stein J. Strukturelle Grundlagen der Leberfunktion. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2006:221-230.

71. Stein J. Molekulare Mikrobiologie und Immunpathogenese von Helicobacter pylori. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:143-150.

72. Stein J. Nahrungsmittelintoxikationen. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:57-64.

73. Stein J. Aussagefähigkeit direkter und indirekter Pankreasfunktionstests. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer-Verlag,, 2006:213-220.

74. Stein J. Prüfung der hepatozellulären Integrität. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2006:231-238.

75. Stein J. Diarrhö. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:319-334.

76. Stein J. Meteorismus. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. Auflage ed. Berlin, Heidelberg, New Yor: Springer-Verlag, 2006:335- 349.

77. Sachs M, Stein J. Infektionskrankheiten des Gastrointestinaltraktes In: Caspary WF, Kist M, Stein J, eds. Infektionen des Peritoneums. 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2006:301-312.

78. Kist M, Stein J. Aereomonas hydrophilia. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:251-252.

79. Kist M, Stein J. Campylobacterenteritis. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006: 215-218.

80. Kist M, Stein J. Salmonellosen – Salmonella enteridis, Salmonella typhimurii. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:207-214.

81. Fuchs KH, Stein J. Magensaftanalyse. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 2. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:39-44.

82. Caspary WF, Stein J. Bakterielle Überbesiedlung. In: Caspary WF, Kist M, Stein J, eds. Infektionskrankheiten des Gastrointestinaltraktes 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2006:301-312.

83. Wächtershäuser A, Jordan A, Stein J. Indikationen unterschiedlicher Sondendiäten In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:558-565.

84. Wächtershäuser A, Falckenbach A, Stein J. Diätetische Beratung und Behandlung. In: Morbus Bechterew In: Falckenbach A, ed. Morbus Bechterew 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:765-782.

85. Stein J, Lembcke B. Bakterielle Fehlbesiedlung In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2004:232-238.

86. Stein J, Jordan A, Hoepffner N. Komplikationen der enteralen Ernährung. In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:576-589.

87. Stein J, Hanisch E. Kurzdarmsyndrom. In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:466-477.

88. Stein J, Faust D. Kolorektale Endometriose In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:342-345.

89. Stein J, Caspary WF. Einheimische und tropische Sprue. In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New Yor: Springer- Verlag, 2004:176-187.

90. Stein J. Gastrointestinaltrakt. In: Falckenbach A, ed. Morbus Bechterew 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:211- 246.

91. Stein J. Der operierte Magen. In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004: 80- 88.

92. Stein J. Prävention und Therapie von NSAR-Schäden. In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2004:111-123.

93. Stein J. Antibiotika-assoziierte Diarrhö. In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:168-175.​

94. Stein J. Pneumatosis cystoides intestinalis In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:239-242.

95. Stein J. Eiweißverlustsyndrom In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:495-499.

96. Schröder O, Stein J. Therapiebedingte Nebenwirkungen In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:209-218.

97. Pommer G, Stein J. Anorektale Krankheiten In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten Berlin, Heidelberg, New York: Springer-Verlag, 2004:355- 370.

98. Milovic V, Stein J, G.M. M. Dietary amines and cancer. In: Wallace HM, Hughes A, eds. Health implications of dietary amines. Volume I. Brussels: European Commission, 2004:110-114.

99. Milovic V, Stein J, caspary WF, et al. Clinical features and diagnosis of malabsorption In: LaMont TA, Rose B, eds. UptoDate in Gastroenterology: Wellesley MA, 2004.

100. Milovic V, Caspary WF, Stein J, et al. Protein-losing gastroenteropathy. In: LaMont TA, Rose B, eds. UptoDate in Gastroenterology: Wellesley MA, 2004.

101. Milovic V, Caspary WF, Stein J. Small bowel diverticula. In: LaMont TA, Rose B, eds. UptoDate in Gastroenterology. Volume 12.2: Wellesley MA, 2004.

102. Mason JB, Milovic V, Stein J, et al. Overview of the treatment of malabsorption. In: LaMont TA, Rose B, eds. UptoDate in Gastroenterologie: Wellesley MA, 2004.

103. Hoepffner N, Stein J. Sonden und Applikationstechniken In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:537-557.

104. Herrlinger K, Stange EF, O. S, et al. Chronisch-entzündliche Darmerkrankungen In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:248-287.

105. Hanisch E, Stein J. Ileus. In: caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:507-513.

106. Gaschott T, Stein J. Medikamentenapplikation über Sonden In: Caspary WF, Mössner J, Stein J, eds. Therapie gastroenterologischer Krankheiten 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2004:566-575.

107. Wolter F, Stein J. Infektionen und Intoxikationen durch Nahrungs- und Genußmittel. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:811-836.

108. Wächtershäuser A, Stein J. Hyperurikämie und Gicht. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-verlag, 2003:811-836.

109. Varlemann H, Stein J. Ernährung bei Herz-Kreislauf-Krankheiten. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2003:499-510.

110. Stein J, Schulz RJ, Stein J. Komplikationen der parenteralen Ernährung. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherpie. 1. ed. Berlin, Heidelberg, New York: Springer- verlag, 2003:408-425.

111. Stein J, Caspary WF. Resorption und Sekretion von Wasser und Elektrolyten. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:56-70.

112. Stein J, Caspary WF. Digestion und Resorption und von Makro- und Mikronährstoffen. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:124-145.​

113. Stein J, Böhles H. Lipid- und Lipoproteinstoffwechsel. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infsionstherapie. 1. ed. Berlin, Heidelberg, New York, : Springer-Verlag, 2003:171-190.

114. Stein J. Ernährung und Stoffwechsel bei SIRS und Sepsis. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:484-497.

115. Stein J. Nukleoproteidstoffwechsel. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:191-196.

116. Scheppach W, Stein J. Ballasstoffgruppe. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed: Springer-Verlag, 2003:230-240.

117. Scheppach W, Pool-Zobel, Stein J. Tumor und Ernährung. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:871-890.

118. Plauth M, Stein J. Ernährung bei Krankheiten der Leber. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. . 1. ed. Berlin, Heidelberg, New York: Springer-verlag, 2003:628-638.

119. Milovic V, Stein J, Caspary WF, et al. Clinical features and diagnosis of malabsorption. In: LaMont TA, Rose B, eds. Update in Gastroenterology (Volume 11.1: Wellesley MA, 2003.

120. Milovic V, Stein J. Carcinogens and co-carcinogens: polyamines, 2003.

121. Milovic V, Caspary WF, Stein J, et al. Protein-losing gastroenteropathy. In: LaMont TA, Rose B, eds. Update in Gastroenterology Volume 11.1: Wellesley MA, 2003.

122. Milovic V, Caspary WF, Stein J. Small bowel diverticula. In: LaMont TA, Rose B, eds. Update in Gastroenterology Volume 11.1: Wellesley MA, , 2003.

123. Mason JB, Milovic V, Stein J, et al. Overview of the treatment of malabsorption. . In: Mason JB, Rose B, eds. UpToDate in Gastroenterology Volume 11.1: Wellesley MA, 2003.

124. Leube B, Stein J. Periphervenöse Ernährung. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:403-407.

125. Jordan A, Stein J. Ernährung bei Krankheiten des Gastrointesinaltraktes. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2003:583-626.

126. Gaschott T, Stein J. Interaktionen zwischen Nahrungsinhaltsstoffen und Medikamenten. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed: Springer-Verlag, 2003:250-270.

127. Gaschott T, Stein J. Medikamentenapplikation über Sonden. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2003:334-342.

128. Druml W, Stein J. Ernährung bei Krankheiten der Niere. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusiostherpie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:519-538.

129. Dormann AJ, Stein J. Sonden- und Applikationstechniken In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003.

130. Bargon J, Böhles H, Stein J. Ernährung bei angeborenen Stoffwechselkrankheiten. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:653-676.

131. Adelmann M, Stein J. Ernährung in der Neurologie und Neurochirurgie. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2003:499-510.

132. Adam O, Stein J. Ernährung bei Krankheiten des Skeletts und der Gelenke. In: Stein J, Jauch KW, eds. Klinische Ernährung und Infusionstherapie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2003:756-7776.

133. Stein J, Schröder O. Prüfung der Leberdurchblutung und des Porto-systemischen Shuntvolumens. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2002:275-284.​

134. Stein J, Schröder O. Prüfung der biliären Sekretionsleistung. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. . 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2002:239-252.

135. Stein J, Schröder O. Resorptionstests. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer-verlag, 2002:125-180.

136. Stein J, Lembcke B. Laktosemalabsorption. In: Schauder P, Ollenschläger G, eds. Ernährungsmedizin. München, Jena: Urban&Fischer, 2002:752-767.

137. Stein J, Braden B. Prüfung der Syntheseleitung und metabolischen Kapazität. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2002:257-274.

138. Stein J, Braden B. Art und Durchführung von Pankreasfunktionsprüfungen. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer-verlag, 2002:181-212.

139. Stein J. Meteorismus. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2002:335-349.

140. Stein J. Diarrhö. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. Berlin, Heidelberg, New York: Springer-Verlag, 2002:319-334.

141. Stein J. Prüfung der Aktivität von Fibrinogenese und Fibrose. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2002:253-256.

142. Stein J. Prüfung der hepatozellulären Integrität. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Spinger- Verlag, 2002:231-238.

143. Stein J. Strukturelle Grundlagen der Leberfunktion. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer- Verlag, 2002:221-230.

144. Stein J. Aussagefähigkeit direkter und indirekter Pankreasfunktionstests. In: Stein J, Wehrmann T, eds. Funktionsdiagnostik in der Gastroenterologie. 1. ed. Berlin, Heidelberg, New York: Springer-Verlag, 2002:213-220.

145. Stein J. Dünndarm und Dickdarm. In: Schauder P, Ollenschläger G, eds. Ernährungsmedizin Jena: Schauder, G. Ollenschläger, 2002:752-767.

146. Stein J. 2002. In: Schauder P, Ollenschläger G, eds. Ernägrungsmedizin. München, Jena: Urban&Fischer, 2002:752-767.

147. Caspary WF, Stein J. Resorptionstests. In: Siewert JR, Harder F, Rothmund M, eds. Praxis der Visceralchirurgie Volume 3. Berlin, Heidelberg, New York Springer-Verlag, 2002:91-101.

148. Wächtershäuser A, Wolter F, Stein J. Onkologie. In: Rechkemmer G, ed. Lexikon der Ernährung Heidelberg, München: Spektum Verlag, 2001.

149. Milovic V, Stein J, Caspary WF, et al. Clinical features and diagnosis of malabsorption. In: LaMont TA, Mason JB, eds. Update in Gastroenterology Volume 9.1: Wellesley MA, 2001.

150. Milovic V, Khomutov AR, Turchsnowa L, et al. Aminooxy analogues of natural polyamines are potent groth inihibitors in colon cancer cells. In: Morgan DML, Milovic V, Stein J, eds. Biologically active amines in food. . Volume V: Polyamines, the gut and cancer 2001.

151. Milovic V, Caspary WF, Stein J, et al. Protein-losing gastroenteropathy. In: LaMont TA, Mason JB, eds. Update in Gastroenterology Volume 9.1: Wellesley MA, 2001.

152. Milovic V, Caspary WF, Stein J. Small bowel diverticula. In: LaMont TA, Rose B, eds. Update in Gastroenterology Volume 9.1: Wellesley MA, 2001.

153. Mason JB, Milovic V, Stein J, et al. Overview of the treatment of malabsorption. In: LaMont TA, Mason JB, eds. Update in Gastroenterology Volume 9.1: Wellesley MA, 2001.

154. Stein J. Leber und Ernährung. In: Caspary WF, Leuschner U, Zeuzem S, eds. Therapie von Leber- und Gallekrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 2000:477-496.

155. Milovic V, Stein J, Caspary WF, et al. Clinical features and diagnosis of malabsorption. In: LaMont TA, Rose B, eds. Up-to-Date in Clinical Medicine. Volume 8.1: Wellesley MA, 2000.​

156. Milovic V, Murphy GM, Bauske R, et al. Characterisation and regulation of polyamine uptake in the gut. In: Morgan DML, White A, SanchezJimenez F, Bardocz S, eds. Cost 917: Biogenically Active Amines in Food, Vol Iv, 2000:74-79.

157. Milovic V, Caspary WF, Stein J, et al. Protein-losing gastroenteropathy: clinical manifestations, diagnosis and treatment. In: LaMont TA, Rose B, eds. Up-to-Date in Clinical Medicine. Volume 8.1: Wellesley MA, 2000.

158. Milovic V, Caspary WF, Stein J. Small bowell diverticula. In: LaMont TA, Rose B, eds. Up-to- Date in Clinical Medicine. Volume 8.1: Wellesley MA, 2000.

159. Milovic V, Bauske R, Turchanowa L, et al. Epidermal growth factor, polyamines, and epithelial remodeling in Caco-2 cells. In: Schulzke JD, Fromm M, Riecken EO, Binder HJ, eds. Epithelial Transport and Barrier Function: Pathomechanisms in Gastrointestinal Disorders. Volume 915, 2000:279-281.

160. Mason JB, Stein J, Milovic V, et al. Overview of the treatment of malabsorption. In: LaMont TA, Rose B, eds. Up-to-Date in Clinical Medicine. Volume 8.1. Wellesley MA, 2000.

161. Stein J, Ries J, Barrett K. Resorption und Sekretion von Wasser und Elektrolyten. In: Caspary WF, Stein J, eds. Darmkrankheiten Berlin, Heidelberg, New York: Springer-Verlag 1999:215- 231.

162. Stein J, Milovic V. Dünndarmdivertikel. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:411-414.

163. Stein J, Milovic V. Gastrointestinal diseases and dosage performanc. In: Dressman JB, Lennernäs H, eds. Methods for assessing oral drug absorption. New York: Marcel Dekker, Inc., 1999:17 – 30.

164. Stein J, Lembcke B. Funktionstests. In: Caspary WF, Stein J, eds. Darmkranlheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:163-180.

165. Stein J, Kottra G. Intestinale Barrierefunktion. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:49-54.

166. Stein J, Caspary WF. Morbus Crohn. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Sringer-Verlag, 1999:421-446.

167. Stein J. Kolorektale Endometriose. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:561-562.

168. Stein J. NSAR und Dickdarm. In: Darmkrankheiten In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:501-506.

169. Stein J. Antibiotika-assoziierte Diarrhö und pseudomembranöse Enterokolitis. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:493-499.

170. Stein J. Kurzdarmsyndrom. In: Caspary WF, Stein J, eds. Darmkrankheiten: Springer-Veralg, 1999:409-418.

171. Stein J. Pneumatosis cystoides intestinalis. In: Caspary WF, Stein J, eds. Darmkrankheiten. Heidelberg, New York: Springer-Verlag, 1999:423-426.

172. Shah P, Caspary WF, Stein J. Infektiöse Diarrhö. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:305-321.

173. Schröder O, Stein J. Schädigungrn an Dünn- und Dickdarm infolge von Zytostatika- und Radiotherapie. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:383-390.

174. Ries J, Stein J. Eosinophile Gastroenteritis. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:363-366.

175. Milovic V, Stein J. Eiweißverlustsyndrom. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:125-130.

176. Menge F, Stein J. Darm und Knochenstoffwechsel. In: Darmkrankheiten. In: Caspary WF, Stein J, eds. Darmkrankheiten. Springer-Verlag, Berlin, Heidelberg, New York, : Sprimger-Verlag, 1999:665-674.

177. Jordan A, Stein J. Enterale und parenterale Ernährung. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:723-743.​

178. Jordan A, Stein J. Ernährung bei Dünn- und Dickdarmkrankheiten. In: Caspary WF, Stein J, eds. Darmkrankheiten. Springer-Verlag, Berlin, Heidelberg: Springer-Verlag, 1999:707-721.

179. Jordan A, Caspary WF, Stein J. Tube feeding in malnutrition. In: Seiler WO, Stähelin HB, eds. Malnutrition in the elderly Darmstadt: Steinkopf-Verlag, 1999:105-112.

180. Holtmeier W, Stein J. Sprue/Zöliakie. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:283-294.

181. Faust D, Stein J. Amyloidose des Dünndarms. In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Sringer-Verlag, 1999:4115-418.

182. Caspary WF, Stein J. Resorption von Nährstoffen und Vitaminen In: Caspary WF, Stein J, eds. Darmkrankheiten. Berlin, Heidelberg, New York: Springer-Verlag, 1999:17-34.

183. Bolder U, Stein J. Intestinale Funktionen beim kritisch Kranken. In: Caspary WF, Stein J, eds. Darmkrankheiten. Springer-Verlag, Berlin, Heidelberg, New York: Springer-Verlag, 1999:675- 682.

184. Turchanowa L, Bauske R, Milovic V, et al. Polyamine als Mediatoren therapeu- tischer Saccharomyces boulardii-Wirkungen. In: Lembcke, B., Kist M, Kirchner T, eds. Ökosystem Darm VIII. Berlin, Heidelberg, New York: Springer-Verlag,, 1998:129-140.

185. Stein J, Menge F. Malabsorption of nutrients and malnutrition in IBD, 1998.

186. Milovic V, Stein J, Caspary WF, et al. Clinical features and diagnosis of malabsorption. In: LaMont T, Rose B, eds. Update in Gastroenterology Volume 6.3, 1998.

187. Milovic V, Caspary WF, J. S. Diverticulitis in the small intestine. In: LaMont T, Rose B, eds. Update in Gastroenterology. Volume 6.3, 1998.

188. Milovic V, Caspary WF, J. S. Protein-losing gastroenteropathy: clinical manifestations, diagnosis and treatment. In: LaMont T, Rose B, eds. Update in Gastroenterology Volume 6.2, 1998.

189. Mason JB, Milovic V, Stein J, et al. Overview of the treatment of malabsorption. . In: LaMont T, Rose B, eds. Update in Gastroenterology. Volume 6.3, 1998.

190. Bauske R, Milovic V, Turhanowa L, et al. Influence of epidermal growth factor transforming growth factor alpha and polyamines on Caco-2 cell proliferation. In: Wiedenmann B, Rosewicz S, Zeitz M, Riecken EO, eds. Intestinal Plasticity in Health and Disease. Volume 859, 1998:198-200.

191. Bauske R, Milovic V, Turhanowa L, et al. Influence of epidermal growth factor/transforming growth factor alpha and polyamines on Caco-2 cell proliferation. In: Wiedenmann B, Rosewicz S, Zeitz M, Riecken EO, eds. Annals of the New York Academy of Sciences; Intestinal plasticity in health and disease. Volume 859, 1998:198-200.

192. Stein J. New fecal tests in the diagnosis of exocrine pancreatic insufficiency. In: Malfertheiner P, DominguezMunoz JE, Schulz U, Lippert H, eds. Diagnostic Procedures in Pancreatic Disease, 1997:277-289.

193. Stein J. Antibiotika-assoziierte Colitis-eine relevante Krankheit? In: Gerok W, Schölmerich J, eds. Klinik der Gegenwart. München: Urban & Schwarzenberg, 1997:26:1-26:14.

194. Stein J, Schröder O. Eicosanoide: Intrazelluläre autokrine Regulatoren epithelialer Funktionen im Gastrointestinaltrakt. In: Caspary WF, Kist M, Lentze MJ, eds. Ökosystem Darm VII. Berlin, Heidelberg, New York: Springer-Verlag, 1996:135-144.

195. Stein J, Ries J. Bakterielle Translokation. Fakten und Phantasie. In: Caspary WF, Kist M, Lentze MJ, eds. ÖkosystemDarm VII Heidelberg: Springer-Verlag, Berlin, 1996:213-224.

196. Stein J. Diagnostic value of fecal enzyme determination and fat analysis in chronic pancreatitis. In: Malfertheimer P, Ditschuneit H, eds. Diagnostic procedures in pancreatic diseases. Berlin, Heidelberg, New-York: Springer-Verlag, 1996:278-289

197. Stein J. Enterales Eiweißverlust-Syndrom und NSAID-Enteropathie. In: Matern S, Caspary WF, Stockbrügger, eds. Diarrhö Darmstadt: Demeter Verlag, 1996.

198. Zeuzem S, Stein J, Caspary WF. Störungen intestinaler Sekretions- und Absorptionsprozesse. In: Caspary WF, Kist M, Zeitz M, eds. Ökosystem Darm VI. Berlin, Heidelberg, New York: Springer-Verlag, 1994:103-116.​

199. Stein J, Schröder O. Luminale Nutrition – Klinische Manifestation von Störungen im Haushalt kurzkettiger Fettsäuren. In: Caspary WF, Kist M, Zeitz M, eds. Ökosystem Darm VI Berlin, Heidelberg, New York: Springer-Verlag, 1994:203-223.

200. Stein J, Ries J, Schröder O, et al. Methodischer Zugang zur Messung der Permeabilität des Dünndarmes. In: Caspary Wf, Kist M, Zeitz P, eds. Ökosystem Darm VI Berlin, Heidelberg, New York: Springer-Verlag, 1994:72-84.

201. Stein J. Diagnostik des Ernährungszustandes. In: Wolfram G, Husemeyer I, eds. Infektiöse Darmerkrankungen, Kinderernährung: Junge & Sohn, 1994:74-99

202. Stein J, Zeuzem S. Störungen des Kaliumhaushaltes bei gastroenterologischen Krankheitsbildern. In: Holtmeier HJ, ed. Kalium-Analytik, Physiologie, Pathophysiologie und Klinik. Stuttgart: Wissenschaftliche Verlagsgesellschaft 1992:137-147.

203. Lembcke B, Stein J. Vitamin deficiency in chronic pancreatitis: assessment and treatment. In: Lankisch P, ed. Pancreatic enzymes in health and disease Berlin, Heidelberg: Springer-Verlag, 1992:155-165.

1. Aksan A, Dignass A, Stein J. Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol 2021:1-2.

2. Aksan A, Dignass A, Stein J. Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Adv Ther 2019.

3. Aksan A, Isik H, Radeke HH, et al. Letter: inconsistency in reporting of hypophosphataemia after intravenous iron-authors’ reply. Aliment Pharmacol Ther 2017;46:643-644.

4. Aksan A, Isik H, Radeke HH, et al. Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies-authors’ reply. Aliment Pharmacol Ther 2017;46:705-706.

5. Aksan A, Isik H, Radeke HH, et al. Editorial: which iron preparation for patients with IBD? Authors’ reply. Aliment Pharmacol Ther 2017;46:195-196.

6. Chiappetta S, Stein J. Refeeding Syndrome: An Important Complication Following Obesity Surgery. Obes Facts 2016;9:12-16.

7. Raithel M, Weidenhiller M, Hahn M, et al. Primary Manifestation of Inflammatory Bowel Disease Following Subcutaneous Autovaccination. J Crohns Colitis 2015;9:802-5.

8. Stein J, Paulke A, Schacher B, et al. An extraordinary form of the Melkersson-Rosenthal syndrome successfully treated with the tumour necrosis factor-alpha blocker adalimumab. BMJ Case Rep 2014;2014.

9. Stein J, Tannich E, Hartmann F. An unusual complication in ulcerative colitis during treatment with azathioprine and infliximab: Isospora belli as ‘Casus belli’. BMJ Case Rep 2013;2013.

10. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012;28:241-3.

11. Kermani F, Aapro M, Stein J, et al. Future good scientific publishing practice will necessitate wider data transparency. Curr Med Res Opin 2012;28:1881-2.

12. Dingermann T, Stein J. Editorial: Pharmazie in unserer Zeit. Probiotika. Pharm Unserer Zeit 2012;41:3.

13. Shastri Y, Povse N, Stein J. A prospective comparative study for new rapid bedside fecal calprotectin test with an established ELISA to assess intestinal inflammation. Clin Lab 2009;55:53-5.

14. Shastri YM, Stein JM. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas. Br J Cancer 2008;99:1366; author reply 1367.

15. Shastri YM, Povse N, Schroder O, et al. Comparison of a novel fecal marker–fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study. Clin Lab 2008;54:389-90.

16. Shastri YM, Loitsch S, Nowak R, et al. Prospective comparative evaluation of an office-based rapid immunological test with a Guaiac-based fecal occult blood test for colorectal cancer screening in general population with average-risk. Clin Lab 2008;54:385-7.

17. Loitsch SM, Shastri Y, Stein J. Stool test for colorectal cancer screening–it’s time to move! Clin Lab 2008;54:473-84.

18. Shastri YM, Stein JM. New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options? Br J Cancer 2007;97:1595-6; author reply 1597.

19. Shastri YM, Stein J. Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening. World J Gastroenterol 2007;13:2768-9.

20. Shastri YM, Stein J. Quantitative immunochemical fecal occult blood test for diagnosing colorectal neoplasia. Ann Intern Med 2007;147:522-3; author reply 523.

21. Bickel M, Ditting T, Watz H, et al. Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after ‘magic mushroom’ abuse. Eur J Emerg Med 2005;12:306-8.

​22. Stein J. 1980-2004: 25 years percutaneous endoscopic gastrostomy (PEG) – feasibilities and limitations. Z Gastroenterol 2004;42:1361-2.

23. Markus BH, Brinkmann L, Hanisch E, et al. Dünndarmtransplantation bei Kurzdarmsyndrom nach fulminanter Mesenterialischämie. Viszeralchirurgie 2001;36:377-382.

24. Weinand I, Stein J. [Cholysarkosin in treatment of bile acid deficiency syndrome]. Z Gastroenterol 1999;37:675-7.

25. Wachtershauser A, Stein J. [Nonsteroidal anti-rheumatic drugs and colon carcinoma: COX versus PPAR]. Z Gastroenterol 1999;37:257-61.

26. Schroder O, Stein J. [Escherichia coli in Crohn dis: pathogenesis or commensal organism?]. Z Gastroenterol 1999;37:469-71.

27. Menge F, Schacherer C, Wigand R, et al. Still’s disease in the adult: differential diagnosis of recurrent pharyngitis with fever of unknown origin and marked hyperferritinaemia. DMW 1999;124:829-832.

28. Feldhaar H, Stein J. [Stress proteins and molecular chaperones–protectors of intestinal epithelial damage?]. Z Gastroenterol 1998;36:193-5.

29. Schroder O, Stein J. [Methotrexate in therapy of chronic inflammatory bowel diseases]. Z Gastroenterol 1996;34:457-8.​

1. Leventi E, Aksan A, Nebe CT, et al. Zinc Protoporphyrin Is a Reliable Marker of Functional Iron Deficiency in Patients with Inflammatory Bowel Disease. Diagnostics (Basel) 2021;11.

2. Farrag K, Ademaj K, Leventi E, et al. Diagnostic utility of low hemoglobin density to detect iron deficiency in patients with inflammatory bowel disease. Annals of Gastroenterology 2021;34.

3. Seeger WA, Thieringer J, Esters P, et al. Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn’s disease. United European Gastroenterol J 2020;8:804-813.

4. Rosano G, Schiefke I, Gohring UM, et al. A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. J Clin Med 2020;9.

5. Radeke HH, Stein J, Van Assche G, et al. A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflamm Intest Dis 2020;5:180-190.

6. Huhn M, Juan MHS, Melcher B, et al. Inflammation-Induced Mucosal KYNU Expression Identifies Human Ileal Crohn’s Disease. J Clin Med 2020;9.

7. Aksan A, Wohlrath M, Iqbal TH, et al. Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease. J Crohns Colitis 2020;14:316-322.

8. Leventi E, Gunthert SJ, Stier C, et al. Is Early Reimplantation of the Duodenal-Jejunal Bypass Liner Viable? Obes Surg 2019;29:1690-1693.

9. Kubesch A, Rueter L, Farrag K, et al. Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort. J Clin Med 2019;8.

10. Hausmann J, Waechtershaeuser A, Behnken I, et al. The role of adipokines in the improvement of diabetic and cardiovascular risk factors within a 52-week weight-loss programme for obesity. Obes Res Clin Pract 2019;13:440-447.

11. Aksan A, Wohlrath M, Iqbal TH, et al. Serum Hepcidin Levels Predict Intestinal Iron Absorption in Patients with Inflammatory Bowel Disease. Clin Lab 2019;65.

12. Stein J, Walper A, Klemm W, et al. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scand J Gastroenterol 2018:1-7.

13. Stein J, Haas JS, Ong SH, et al. Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany – a real-world evidence analysis. Clinicoeconomics and Outcomes Research 2018;10:93-103.

14. Stein J, Aksan A, Klemm W, et al. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice. J Crohns Colitis 2018;12:826-834.

15. Schulze H, Esters P, Hartmann F, et al. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scand J Gastroenterol 2018:1-7.

16. Hagel AF, Albrecht H, Dauth W, et al. Plasma concentrations of ascorbic acid in a cross section of the German population. J Int Med Res 2018;46:168-174.

17. Karimian S, Stein J, Bauer B, et al. Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity. Diabetes Metab Syndr Obes 2017;10:19-25.

18. Aksan A, Isik H, Radeke HH, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:1303-1318.

19. Karimian S, Stein J, Bauer B, et al. Impact of Severe Obesity and Weight Loss on Systolic Left Ventricular Function and Morphology: Assessment by 2-Dimensional Speckle-Tracking Echocardiography. J Obes 2016;2016:2732613.

20. Scherzberg MC, Kiehl A, Zivkovic A, et al. Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action. Toxicol Appl Pharmacol 2015;287:67-76.

21. Iqbal T, Stein J, Sharma N, et al. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Dig Dis Sci 2015;60:1375-81.

22. Bach M, Geisel T, Martin J, et al. Efficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice. Anemia 2015;2015:647930.

23. Loitsch SM, Reuter KC, Oremek GM, et al. Comparison of a new microbiological assay with a standard high-performance liquid chromatographic method for determination of vitamin B6 in serum. Clin Lab 2014;60:1035-41.

24. Karner M, Kocjan A, Stein J, et al. First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 2014;109:1041-51.

25. Kaminski BM, Weigert A, Scherzberg MC, et al. Resveratrol-induced potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of human monocyte-derived macrophages. Apoptosis 2014;19:1136-47.

26. Iqbal T, Stein J, Sharma N, et al. Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia. Dig Dis Sci 2014.

27. Geisel T, Martin J, Schulze B, et al. An etiologic profile of anemia in 405 geriatric patients. Anemia 2014;2014:932486.

28. Blumenstein I, Dignass A, Vollmer S, et al. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis 2014;8:1308-14.

29. Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol 2013.

30. Martin J, Geisel T, Maresch C, et al. Inadequate Nutrient Intake in Patients with Celiac Disease: Results from a German Dietary Survey. Digestion 2013;87:240-246.

31. Kulnigg-Dabsch S, Schmid W, Howaldt S, et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis 2013;19:1609-16.

32. Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2013:269- 277.

33. Reuter KC, Loitsch SM, Dignass AU, et al. Selective non-steroidal glucocorticoid receptor agonists attenuate inflammation but do not impair intestinal epithelial cell restitution in vitro. PLoS One 2012;7:e29756.

34. Reuter KC, Grunwitz CR, Kaminski BM, et al. Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther 2012;341:68-80.

35. Blumenstein I, Borger D, Loitsch S, et al. A glycerin hydrogel-based wound dressing prevents peristomal infections after percutaneous endoscopic gastrostomy (PEG): a prospective, randomized study. Nutr Clin Pract 2012;27:422-5.

36. Kaminski BM, Weigert A, Brune B, et al. Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death. Cancer Chemother Pharmacol 2011;67:1167-78.

37. Hoffmann P, Sturm A, Stein J, et al. Interferon-gamma modulates intestinal epithelial cell function in-vitro through a TGFbeta-dependent mechanism. Regul Pept 2011;168:27-31.

38. Hirche TO, Stein J, Hirche H, et al. Increased levels of anti-glycan antibodies in patients with cystic fibrosis. Eur J Med Res 2011;16:385-90.

39. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141:846-853 e1-2.

40. Blumenstein I, Herrmann E, Filmann N, et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet- based study. J Crohns Colitis 2011;5:203-10.

41. Kaminski BM, Loitsch SM, Ochs MJ, et al. Isothiocyanate sulforaphane inhibits protooncogenic ornithine decarboxylase activity in colorectal cancer cells via induction of the TGF-beta/Smad signaling pathway. Mol Nutr Food Res 2010;54:1486-96.

42. Holtmann MH, Krummenauer F, Claas C, et al. Significant differences between Crohn’s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci 2010;55:1066-78.

43. Hartmann F, Stein J. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010;32:368-76.

44. Schwab M, Reynders V, Steinhilber D, et al. Combined treatment of Caco-2 cells with butyrate and mesalazine inhibits cell proliferation and reduces Survivin protein level. Cancer Lett 2009;273:98-106.

45. Schneider AR, Klueber S, Posselt HG, et al. Application of the glucose hydrogen breath test for the detection of bacterial overgrowth in patients with cystic fibrosis–a reliable method? Dig Dis Sci 2009;54:1730-5.

46. Blumenstein I, Bock H, Zosel C, et al. [Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a prospective multicentre online-based trial]. Z Gastroenterol 2009;47:1045-51.

47. Shastri YM, Povse N, Schroder O, et al. Comparison of a novel fecal marker–fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study. Clin Lab 2008;54:389-90.

48. Shastri YM, Loitsch S, Hoepffner N, et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol 2008;103:1496-504.

49. Shastri YM, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008;121:1099-106.

50. Schwab M, Reynders V, Loitsch S, et al. The dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in intestinal epithelial cells. Immunology 2008;125:241-51.

51. Schwab M, Reynders V, Loitsch S, et al. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 2008;29:1407-14.

52. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008;324:23-33.

53. Blumenstein I, Bock H, Weber C, et al. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm Bowel Dis 2008;14:53-60.

54. Ulrich S, Huwiler A, Loitsch S, et al. De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. Biochem Pharmacol 2007;74:281-9.​

55. Schwab M, Reynders V, Shastri Y, et al. Role of nuclear hormone receptors in butyrate- mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol Immunol 2007;44:2107-14.

56. Schwab M, Reynders V, Loitsch S, et al. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol 2007;44:3625-32.

57. Schroder O, Naumann M, Shastri Y, et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-42.

58. Schneider AR, Jepp K, Murczynski L, et al. The inulin hydrogen breath test accurately reflects orocaecal transit time. Eur J Clin Invest 2007;37:802-7.

59. Reinshagen M, Schutz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53:1306-14.

60. Hauser W, Musial F, Caspary WF, et al. Predictors of irritable bowel-type symptoms and healthcare-seeking behavior among adults with celiac disease. Psychosom Med 2007;69:370- 6.

61. Gutt CN, Brinkmann L, Mehrabi A, et al. Dietary omega-3-polyunsaturated fatty acids prevent the development of metastases of colon carcinoma in rat liver. Eur J Nutr 2007;46:279-85.

62. Daniel C, Sartory NA, Zahn N, et al. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol 2007;44:3305-16.

63. Daniel C, Sartory N, Zahn N, et al. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 2007;178:2458- 68.

64. Ulrich S, Loitsch SM, Rau O, et al. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 2006;66:7348-54.

65. Shastri YM, Naumann M, Oremek GM, et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 2006;119:2651-6.

66. Schwab M, Reynders V, Ulrich S, et al. PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 2006;11:1801-11.

67. Schroder O, Yudina Y, Sabirsh A, et al. 15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells. J Lipid Res 2006;47:1071-80.

68. Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn’s disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006;18:11-6.

69. Schneider AR, Teuber G, Paul K, et al. Patient age is a strong independent predictor of 13C- aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection. Clin Exp Pharmacol Physiol 2006;33:300-4.

70. Schneider AR, Hammerstingl R, Heller M, et al. Does secretin-stimulated MRCP predict exocrine pancreatic insufficiency?: A comparison with noninvasive exocrine pancreatic function tests. J Clin Gastroenterol 2006;40:851-5.

71. Pirlich M, Schutz T, Norman K, et al. The German hospital malnutrition study. Clin Nutr 2006;25:563-72.

72. Holtmann MH, Krummenauer F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 2006;51:1516-24.

73. Hoepffner N, Shastri YM, Hanisch E, et al. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther 2006;23:145- 54.​

74. Hauser W, Gold J, Stein J, et al. Health-related quality of life in adult coeliac disease in Germany: results of a national survey. Eur J Gastroenterol Hepatol 2006;18:747-54.

75. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005;51:2282-8.

76. Ulrich S, Wachtershauser A, Loitsch S, et al. Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation. Exp Cell Res 2005;310:196-204.

77. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-9.

78. Schneider AR, Seifert H, Trojan J, et al. Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater–an age-matched, controlled study. Z Gastroenterol 2005;43:1123-7.

79. Schneider A, Funk B, Caspary W, et al. Monoclonal versus polyclonal ELISA for assessment of fecal elastase concentration: pitfalls of a new assay. Clin Chem 2005;51:1052-4.

80. Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol 2005;57:709-19.

81. Furst T, Bott C, Stein J, et al. Enteric-coated cholylsarcosine microgranules for the treatment of short bowel syndrome. J Pharm Pharmacol 2005;57:53-60.

82. Blumenstein I, Keseru B, Wolter F, et al. The chemopreventive agent resveratrol stimulates cyclic AMP-dependent chloride secretion in vitro. Clin Cancer Res 2005;11:5651-6.

83. Zgouras D, Becker U, Loitsch S, et al. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 2004;316:693-7.

84. Schroder O, Schrott M, Blumenstein I, et al. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol 2004;42:663-7.

85. Schroder O, Naumann M, Stein J. Anti-Saccharomyces cerevisiae antibodies and response to infliximab in refractory Crohn’s disease. Aliment Pharmacol Ther 2004;20:823-4.

86. Schroder O, Blumenstein I, Schulte-Bockholt A, et al. Combining infliximab and methotrexate in fistulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 2004;19:295-301.

87. Naumann M, Schaum B, Oremek GM, et al. [Faecal pyruvate kinase type M2–a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study]. Dtsch Med Wochenschr 2004;129:1806-7.

88. Zgouras D, Wachtershauser A, Frings D, et al. Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation. Biochem Biophys Res Commun 2003;300:832-8.

89. Wolter F, Turchanowa L, Stein J. Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis 2003;24:469-74.

90. Schroder O, Sjostrom M, Qiu H, et al. Molecular and catalytic properties of three rat leukotriene C(4) synthase homologs. Biochem Biophys Res Commun 2003;312:271-6.

91. Jordan A, Stein J. Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. Eur J Nutr 2003;42:324-31.

92. Faust D, Menge F, Armbruster FP, et al. Increased serum bone sialoprotein concentrations in patients with Crohn’s disease. Z Gastroenterol 2003;41:243-7.

93. Blumenstein I, Gerhard R, Ries J, et al. Regulation of mastoparan-induced increase of paracellular permeability in T84 cells by RhoA and basolateral potassium channels. Biochem Pharmacol 2003;65:1151-61.

94. Wolter F, Stein J. Resveratrol enhances the differentiation induced by butyrate in caco-2 colon cancer cells. J Nutr 2002;132:2082-6.

95. Wolter F, Clausnitzer A, Akoglu B, et al. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 2002;132:298-302.

96. Turchanowa L, Shvetsov AS, Demin AV, et al. Insufficiently charged isosteric analogue of spermine: interaction with polyamine uptake, and effect on Caco-2 cell growth. Biochem Pharmacol 2002;64:649-55.

97. Trojan J, Povse N, Schroder O, et al. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. Z Gastroenterol 2002;40:921-4.

98. Stein J, Schulte-Bockholt A, Sabin M, et al. A randomized prospective trial of immediate vs. next-day feeding after percutaneous endoscopic gastrostomy in intensive care patients. Intensive Care Med 2002;28:1656-60.

99. Milovic V, Teller IC, Faust D, et al. Effects of deoxycholate on human colon cancer cells: apoptosis or proliferation. Eur J Clin Invest 2002;32:29-34.

100. Faust D, Raschke K, Hormann S, et al. Regulation of alpha1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells. Clin Exp Immunol 2002;128:279-84.

101. Faust D, Akoglu B, Zgouras D, et al. Anti-inflammatory drugs modulate C1q secretion in human peritoneal macrophages in vitro. Biochem Pharmacol 2002;64:457-62.

102. Wolter F, Akoglu B, Clausnitzer A, et al. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 2001;131:2197-203.

103. Wachtershauser A, Stein J. Butyrate-induced differentiation of Caco-2 cells occurs independently from p27. Biochem Biophys Res Commun 2001;281:295-9.

104. Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001;22:1061-7.

105. Turchanowa L, Dauletbaev N, Milovic V, et al. Nonsteroidal anti-inflammatory drugs stimulate spermidine/spermine acetyltransferase and deplete polyamine content in colon cancer cells. Eur J Clin Invest 2001;31:887-93.

106. Milovica V, Turchanowa L, Khomutov AR, et al. Hydroxylamine-containing inhibitors of polyamine biosynthesis and impairment of colon cancer cell growth. Biochem Pharmacol 2001;61:199-206.

107. Milovic V, Turchanowa L, Stein J, et al. Transepithelial transport of putrescine across monolayers of the human intestinal epithelial cell line, Caco-2. World J Gastroenterol 2001;7:193-7.

108. Milovic V, Teller IC, Murphy GM, et al. Deoxycholic acid stimulates migration in colon cancer cells. Eur J Gastroenterol Hepatol 2001;13:945-9.

109. Milovic V, Faust D, Turchanowa L, et al. Permeability characteristics of polyamines across intestinal epithelium using the Caco-2 monolayer system: comparison between transepithelial flux and mitogen-stimulated uptake into epithelial cells. Nutrition 2001;17:462-6.

110. Jordan A, Stein J. Modulation of epidermal growth factor-induced cell proliferation by an omega-3 fatty-acid-containing lipid emulsion on human pancreatic cancer cell line Mia Paca- 2. Nutrition 2001;17:474-5.

111. Gaschott T, Wachtershauser A, Steinhilber D, et al. 1,25-Dihydroxycholecalciferol enhances butyrate-induced p21(Waf1/Cip1) expression. Biochem Biophys Res Commun 2001;283:80-5.

112. Gaschott T, Steinhilber D, Milovic V, et al. Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells. J Nutr 2001;131:1839-43.

113. Gaschott T, Maassen CU, Stein J. Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells. Anticancer Res 2001;21:2815-9.​

114. Faust D, Spirchez Z, Armbruster FP, et al. Determination of alpha1-proteinase inhibitor by a new enzyme linked immunosorbant assay in feces, serum and an enterocyte-like cell line. Z Gastroenterol 2001;39:769-74.

115. Faust D, Hormann S, Friedrich-Sander M, et al. Butyrate and the cytokine-induced alpha1- proteinase inhibitor release in intestinal epithelial cells. Eur J Clin Invest 2001;31:1060-3.

116. Bender A, Breves G, Stein J, et al. Colonic fermentation as affected by antibiotics and acidic pH: Application of an in vitro model. Z Gastroenterol 2001;39:911-8.

117. Akoglu B, Faust D, Milovic V, et al. Folate and chemoprevention of colorectal cancer: Is 5- methyl-tetrahydrofolate an active antiproliferative agent in folate-treated colon-cancer cells? Nutrition 2001;17:652-3.

118. Wachtershauser A, Steinhilber D, Loitsch SM, et al. Expression of 5-lipoxygenase by human colorectal carcinoma Caco-2 cells during butyrate-induced cell differentiation. Biochem Biophys Res Commun 2000;268:778-83.

119. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun 2000;272:380-5.

120. Turchanowa L, Rogozkin VA, Milovic V, et al. Influence of physical exercise on polyamine synthesis in the rat skeletal muscle. Eur J Clin Invest 2000;30:72-8.

121. Stein J, Zores M, Schroder O. Short-chain fatty acid (SCFA) uptake into Caco-2 cells by a pH- dependent and carrier mediated transport mechanism. Eur J Nutr 2000;39:121-5.

122. Stein J, Bauske R, Gerhard R. Analysis of low-molecular-weight GTP-binding proteins in two functionally different intestinal epithelial cell lines. Ann N Y Acad Sci 2000;915:223-30.

123. Schroder O, Opritz J, Stein J. Substrate and inhibitor specificity of butyrate uptake in apical membrane vesicles of the rat distal colon. Digestion 2000;62:152-8.

124. Milovic V, Teller IC, Turchanowa L, et al. Effect of structural analogues of propionate and butyrate on colon cancer cell growth. Int J Colorectal Dis 2000;15:264-70.

125. Milovic V, Stein J, Odera G, et al. Low-dose deoxycholic acid stimulates putrescine uptake in colon cancer cells (Caco-2). Cancer Lett 2000;154:195-200.

126. Milovic V, Bauske R, Turchanowa L, et al. Epidermal growth factor, polyamines, and epithelial remodeling in Caco-2 cells. Epithelial Transport and Barrier Function: Pathomechanisms in Gastrointestinal Disorders. Volume 915, 2000:279-281.

127. Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:171-6.

128. Chow KU, Rummel MJ, Weidmann E, et al. Induction of apoptosis by 2-chloro- 2’deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Leuk Lymphoma 2000;36:559-67.

129. Chow KU, Ries J, Weidmann E, et al. Induction of apoptosis using 2′,2′ difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 2000;79:485-92.

130. Breves G, Faul K, Schroder B, et al. Application of the colon-simulation technique for studying the effects of Saccharomyces boulardii on basic parameters of porcine cecal microbial metabolism disturbed by clindamycin. Digestion 2000;61:193-200.

131. Bauske R, Milovic V, Turchanowa L, et al. EGF-stimulated polyamine accumulation in the colon carcinoma cell line, Caco-2. Digestion 2000;61:230-6.

132. Schroder O, Hess S, Caspary WF, et al. Mediation of differentiating effects of butyrate on the intestinal cell line Caco-2 by transforming growth factor-beta 1. Eur J Nutr 1999;38:45-50.

133. Gebhardt BR, Ries J, Caspary WF, et al. Superoxide: a major factor for stress protein induction in reoxygenation injury in the intestinal cell line Caco-2. Digestion 1999;60:238-45.

134. Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 1998;274:G203-9.

135. Milovic V, Turhanowa L, Fares FA, et al. S-adenosylmethionine decarboxylase activity and utilization of exogenous putrescine are enhanced in colon cancer cells stimulated to grow by EGF. Z Gastroenterol 1998;36:947-54.

136. Milovic V, Caspary WF, Stein J. Polyamine uptake across the basolateral membrane of the enterocyte is mediated by a high-affinity carrier: a study using isolated basolateral membrane vesicles. Digestion 1998;59:60-8.

137. Bauske R, Milovic V, Turhanowa L, et al. Influence of epidermal growth factor/transforming growth factor alpha and polyamines on Caco-2 cell proliferation. Ann N Y Acad Sci 1998;859:198-200.

138. Ries J, Stein J, Traynor-Kaplan AE, et al. Dual role for AlF4(-)-sensitive G proteins in the function of T84 epithelial cells: transport and barrier effects. Am J Physiol 1997;272:C794- 803.

139. Rehner GI, Stein J. High-performance liquid chromatographic determination of biotin in biological materials after crown ether-catalyzed fluorescence derivatization with panacyl bromide. Methods Enzymol 1997;279:286-95.

140. Amelsberg A, Schteingart CD, Stein J, et al. Intestinal absorption of sodium dodecyl sulfate in the rodent: evidence for paracellular absorption. Am J Physiol 1997;272:G498-506.

141. Stein J, Schroder O, Bonk M, et al. Induction of glutathione-S-transferase-pi by short-chain fatty acids in the intestinal cell line Caco-2. Eur J Clin Invest 1996;26:84-7.

142. Stein J, Schoonbroodt D, Jung M, et al. [Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function]. Gastroenterol Clin Biol 1996;20:424-9.

143. Stein J, Purschian B, Zeuzem S, et al. Quantification of fecal carbohydrates by near-infrared reflectance analysis. Clin Chem 1996;42:309-12.

144. Stein J, Jung M, Sziegoleit A, et al. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem 1996;42:222-6.

145. Schroder O, Rathner W, Caspary WF, et al. Bile acid-induced increase of rat colonic apical membrane fluidity and proton permeability. Z Gastroenterol 1996;34:365-70.

146. Scheppach W, Bartram H, Richter F, et al. Treatment of distal ulcerative colitis with short- chain fatty acid enemas. A placebo-controlled trial. Dig Dis Sci 1996;41:2254-2259.

147. Stuck K, Faul K, Hylla S, et al. The application of a semi-continuous colon simulation technique (Cositec) for studying the effects of clindamycin on microbial hindgut metabolism. Z Gastroenterol 1995;33:241-6.

148. Stryjek-Kaminska D, Piiper A, Stein J, et al. Epidermal growth factor receptor signaling in rat pancreatic acinar cells. Pancreas 1995;10:274-80.

149. Stein J, Schroder O, Milovic V, et al. Mercaptopropionate inhibits butyrate uptake in isolated apical membrane vesicles of the rat distal colon. Gastroenterology 1995;108:673-9.

150. Stein J, Hahn A, Rehner G. High-performance liquid chromatographic determination of nicotinic acid and nicotinamide in biological samples applying post-column derivatization resulting in bathmochrome absorption shifts. J Chromatogr B Biomed Appl 1995;665:71-8.

151. Stein J, Gerhard R, Zeuzem S, et al. Subcellular distribution of small GTP-binding proteins in the intestinal cell line Caco-2. Eur J Clin Invest 1995;25:793-5.

152. Schroder O, Gerhard R, Caspary WF, et al. Isolation and characterization of apical membrane vesicles of the rat distal colon. Res Exp Med (Berl) 1995;195:333-42.

153. Milovic V, Stein J, Piiper A, et al. Characterization of putrescine transport across the intestinal epithelium: study using isolated brush border and basolateral membrane vesicles of the enterocyte. Eur J Clin Invest 1995;25:97-105.

154. Milovic V, Deubner C, Zeuzem S, et al. EGF stimulates polyamine uptake in Caco-2 cells. Biochem Biophys Res Commun 1995;206:962-8.

155. Breves G, Schroder B, Stein J. Transepithelial transport of short chain fatty acids and their metabolism in pig hindgut. Dtsch Tierarztl Wochenschr 1995;102:159-60.

156. Zeuzem S, Stryjek-Kaminska D, Caspary WF, et al. Effect of a Rab3A effector domain-related peptide, CCK, and EGF in permeabilized pancreatic acini. Am J Physiol 1994;267:G350-6.​

157. Stein J, Zeuzem S, Uphoff K, et al. Effects of prostaglandins and indomethacin on gastric emptying in the rat. Prostaglandins 1994;47:31-40.

158. Stein J, Scheuermann EH, Yazdi R, et al. Reduced postheparin plasma diamine oxidase activity in patients with chronic renal failure. Z Gastroenterol 1994;32:236-9.

159. Stein J, Purschian B, Lembcke B, et al. Validation of near infrared reflectance analysis (NIRA) for assessment of fecal fat, nitrogen and water. A new approach to malabsorption syndromes. Eur J Gastroen Hepat 1994;6:889-894.

160. Stein J, Milovic V, Gerhard R, et al. Simultaneous preparation of rabbit intestinal brush border and basolateral membrane vesicles. Res Exp Med (Berl) 1994;194:305-12.

161. Stein J, Daniel H, Whang E, et al. Rapid postabsorptive metabolism of nicotinic acid in rat small intestine may affect transport by metabolic trapping. J Nutr 1994;124:61-6.

162. Piiper A, Stryjek-Kaminska D, Stein J, et al. Tyrphostins inhibit secretagogue-induced 1,4,5-IP3 production and amylase release in pancreatic acini. Am J Physiol 1994;266:G363-71.

163. Milovic V, Stein J, Ruppert S, et al. Preparation of basolateral membrane vesicles from rat enterocytes: influence of different gradient media. Physiol Res 1994;43:75-81.

164. Stein J, Zeuzem S, Caspary W. Fluorimetric high-performance liquid chromatography of free fatty acids using panacyl bromide J Liq Chromatogr 1993;16:2915-22.

165. Piiper A, Stryjek-Kaminska D, Stein J, et al. Effects of guanine nucleotides on bombesin- stimulated signal transduction in rat pancreatic acinar cells. Res Exp Med (Berl) 1993;193:323-35.

166. Piiper A, Stryjek-Kaminska D, Stein J, et al. A synthetic peptide of the effector domain of rab3A stimulates inositol 1,4,5-trisphosphate production in digitonin-permeabilized pancreatic acini. Biochem Biophys Res Commun 1993;192:1030-6.

167. Falkenbach A, Unkelbach U, Boehm BO, et al. Bone metabolism before and after irradiation with ultraviolet light. Eur J Appl Physiol Occup Physiol 1993;66:55-9.

168. Stein J, Milovic V, Lembcke B, et al. Characteristics of putrescine uptake by human brush border membrane vesicles. Z Gastroenterol 1992;30:841-5.

169. Stein J, Kulemeier J, Lembcke B, et al. Simple and rapid method for determination of short- chain fatty acids in biological materials by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1992;576:53-61.

170. Stein J, Hahn A, Lembcke B, et al. High-performance liquid chromatographic determination of biotin in biological materials after crown ether-catalyzed fluorescence derivatization with panacyl bromide. Anal Biochem 1992;200:89-94.

171. Sander S, Hahn A, Stein J, et al. Comparative studies on the high performance liquid chromatographic determination of thiamine and its phophate esters with chloroethylthiamine a an internal standard using pre- and post column derivatisation procedures. J Chromatogr B 1991;558:115-124.

172. Hahn A, Stein J, Rump U, et al. Opitimized high performance liquid chromatographic procedure for the separation and quatification of the main folacins and some derivatives. J Chromatogr B Biomed Appl 1991;540:207-215.​